National Institutes of Health Pathways to Prevention Workshop: Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention

Ann Intern Med. 2019 Jul 2;171(1):51-57. doi: 10.7326/M19-0961. Epub 2019 Apr 23.


On 30 and 31 October 2018, the National Institutes of Health convened the Pathways to Prevention (P2P) Workshop: Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention to assess the available evidence on long-term (>3 years) use of drug therapies to prevent osteoporotic fractures and identify research gaps and needs for advancing the field. The workshop was cosponsored by the NIH Office of Disease Prevention (ODP), National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute on Aging. A multidisciplinary working group developed the agenda, and an Evidence-based Practice Center prepared an evidence report through a contract with the Agency for Healthcare Research and Quality to facilitate the discussion. During the 1.5-day workshop, invited experts discussed the body of evidence and attendees had the opportunity to comment during open discussions. After data from the evidence report, expert presentations, and public comments were weighed, an unbiased independent panel prepared a draft report that was posted on the ODP Web site for 5 weeks for public comment. This final report summarizes the panel's findings and recommendations. Current gaps in knowledge are highlighted, and a set of recommendations for new, strengthened research to better inform the long-term use of osteoporotic drug therapies is delineated.

Publication types

  • Consensus Development Conference, NIH

MeSH terms

  • Biomedical Research*
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / therapeutic use*
  • Decision Making, Shared
  • Denosumab / adverse effects
  • Denosumab / therapeutic use
  • Diphosphonates / adverse effects
  • Diphosphonates / therapeutic use
  • Duration of Therapy
  • Evidence-Based Medicine
  • Female
  • Humans
  • National Institutes of Health (U.S.)
  • Osteoporotic Fractures / prevention & control*
  • Patient Acceptance of Health Care
  • Risk Assessment
  • United States


  • Bone Density Conservation Agents
  • Diphosphonates
  • Denosumab